A PIPELINE OF HIGHLY SELECTIVE DRUG CANDIDATES

Research
Preclinical
Phase 1
Phase 2
PRN1008: BTK inhibitor / Pemphigus Vulgaris
    
PRN1008: BTK inhibitor / Second Indication
    
PRN1371: FGFR inhibitor / Multiple Cancers
    
PRN2246: BTK inhibitor / CNS, Autoimmune/Inflamm
    
Immunoproteasome Inhibitor: Autoimmune / Inflamm
    
The advantage of Tailored Covalency®

Traditional oral small molecule drugs are convenient, but often have side effects because they may not be selective.

Injectable antibody drugs are highly specific therapies, but an injection is not convenient for the patient.

…the best of both worlds

Principia’s novel approach to drug development combines the dosing convenience of a small molecule drug with characteristics of an antibody. Our drugs are designed to be effective, potent, selective, durable and safer than traditional small molecule drugs.

Learn More